(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯内酰胺
• 英文名称: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
• 化学式: C₅₁H₇₉NO₁₃
• 分子量: 914.2
• InChiKey: QFJCIRLUMZQUOT-WMVIXHMVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  65
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  195
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY
  申请人：Wang Yan

  公开号：US20110091524A1

  公开（公告）日：2011-04-21

  The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.

  本发明提供了方便确定受试者的癌症状况是否对IGF1R抑制剂具有响应的方法。该发明包括患者选择方法和治疗方法。
• METHODS OF TREATMENT
  申请人：Wang Yan

  公开号：US20110262525A1

  公开（公告）日：2011-10-27

  This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.

  本发明涉及用于治疗各种癌症的组合物和方法。本申请还涵盖了治疗组合物和使用方法。
• HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY
  申请人：Basso-Porcaro Andrea Dawn

  公开号：US20110009387A1

  公开（公告）日：2011-01-13

  The present invention relates e.g., to methods for predicting cellular sensitivity to farnesyl protein transferase inhibitors, such as lonafarnib; manumycin A; FTI-276; L-744832; BMS-214662; tipifarnib; BMS-316810K. The methods involve determining if malignant cells exhibit increased expression. of phosphorylated histone H2Ax following contact of one or more of said cells with said inhibitor.

  本发明涉及例如，用于预测细胞对法尼酰蛋白转移酶抑制剂（如洛纳法尼布、马努霉素A、FTI-276、L-744832、BMS-214662、替匹法尼布、BMS-316810K）的敏感性的方法。该方法涉及确定恶性细胞是否在与该抑制剂中的一个或多个细胞接触后表现出磷酸化组蛋白H2Ax的表达增加。
• ANTI-IGF1R
  申请人：Wang Yan

  公开号：US20110014117A1

  公开（公告）日：2011-01-20

  The present invention relates in part to anti-IGF1R antibodies and antigen-binding compositions thereof along with methods of use thereof. For example, methods of treating medical disorders such as cancer are covered.

  本发明部分涉及抗IGF1R抗体及其抗原结合组成物，以及其使用方法。例如，涵盖了治疗癌症等医学疾病的方法。
• Immunosuppressant drug extraction reagent for immunoassays
  申请人：Grenier Frank C.

  公开号：US20080020401A1

  公开（公告）日：2008-01-24

  An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays.